



From Insulins to GLP-1 Receptors:

Preparing for the Next Wave of Off-Patent Molecules







Supporting You at Every Stage of your Drug Development Journey

Preclinical

- Discovery
- Bioanalysis
- Toxicology

Biopharma

- Clinical Bioanalysis solution for BioTherapeutics
- Non-Clinical
 Characterization
 Solutions Discovery
 Biology, Bioprocess,
 and Analytical
 Characterization

Clinical Studies

- Phase I Healthy
 Volunteer study
 for Antidiabetic drug
- Type 2 Diabetic Phase II/Phase III Trials
- Phase IV & PMS Studies
- Healthy Volunteer
 Bioequivalence (BE)/
 Bioavailability (BA)
 studies involving
 Glucose Clamp & GLP1

Bioanalytical Solutions

Bioanalytical Method
 Development and
 Validations for
 NCEs & Generics



State-of-the-Art Infrastructure & Expertise for Endocrinology Drug Development

Operational Capabilities

- Experience in Recruiting 400+ subjects
- 38 Endocrinologists across 20 sites
- GCP Trained Study Staff
- Trained doctor and team in Advanced Cardiac Life Support (ACLS) and Basic Life Support (BLS)
- Utilized 1322 clamps in 15 studies
- Experience ranging from 8 to 36 hours per clamp
- Capable of performing 4 to 6 clamps per day for efficient study completion
- Trained senior staff specialized in Endocrinology studies with a PHD in Medicine and Pharmacology.
- Tertiary care tie-up with Sterling hospital for advanced medical care

Advanced Facilities

- Yellow Spring Instruments(YSI) for accurate blood glucose assessment
- 12 state-of-the-art beds with backup generators
- 30-bed Phase-I capacity across two units.
- Special care area with cardiac monitor, defibrillator, ECG machine, suction machine, oxygen cylinder, cardiac arrest kit, and anaphylaxis kit.
- Resuscitation centre with a fully equipped resuscitation trolley and emergency medications



Stay Ahead of the Curve: Veeda's Solution for Molecules going Off-Patent

Biotherapeutics Going off Patent



- Dulaglutide
- Exenatide

Abaloparatide

- Insulin degludec
- Semaglutide
- Insulin degludec#liraglutide

Molecules Requiring Healthy Volunteer Generic Bioequivalence (BE) Studies:




- Empagliflozin
- Linagliptin
- Empagliflozin#metformin
- Linagliptin#metformin
- Metformin

- Canagliflozin
- Canagliflozin#metformin
- Empagliflozin#linagliptin
- Dapagliflozin#metformin



Diverse Insulin Portfolio: Successfully executed 12 Different Studies

Insulin Product Clinical Trials Complexity Bioanalytical Trials Complexity Individualized titration Sensitive long-acting assays Insulin Glargine Metabolite analysis Hypoglycemia management Postprandial glycemic control Rapid-acting assays Insulin Aspart Injection site impact Injection site rotation Development of Wosulin-specific assays Individual patient response Insulin Wosulin Pharmacokinetic/pharmacodynamic Hypoglycemia risk assessment differences







Insights into Sitagliptin: Diabetes Care with DPP-4 Inhibitors

> DPP-4 inhibitors like Sitagliptin prolong the action of GLP-1 and GIP, resulting in increased insulin secretion and decreased glucagon secretion. This mechanism ultimately helps to lower blood sugar levels in patients with type 2 diabetes.

Drug

Sitagliptin

Clinical Trials Complexity

- Assessment of DPP-4 inhibition
- Glycemic control

Bioanalytical Trials Complexity

- Specific assays for sitagliptin
- Metabolite analysis

Completed Oral Antidiabetic Glucose Clamp Studies with 20 Subjects




Biosimilar Experience across Different Diabetic Molecules

- > Specialized in clinical and bioanalytical evaluation, with expertise in immunogenicity assessment using advanced techniques such as HPLC, ELISA and LC-MS/MS
- Biosimilar development includes rigorous analytical techniques such as intact mass analysis, peptide mapping, and amino acid sequencing by focusing on peptides like Insulin, & C-Peptide
- Advanced methods like capillary electrophoresis to assess molecular heterogeneity and confirm the equivalence of our biosimilar

Completed Healthy Volunteer GLP-1 Studies for -

Liraglutide

Semaglutide



India: +91 79677 73000 Europe: +30 210 699 7247





